1 Protease-activated receptors (PARs) 1 and 2 modulate the gastric and intestinal smooth muscle motility in vitro. In the present study, we examined if activation of PAR-2 and PAR-1 could alter gastrointestinal transit in mice. 2 Intraperitoneal administration of the PAR-2-activating peptide SLIGRL-NH 2 , but not the inactive control LSIGRL-NH 2 , at 1±5 mmol kg 71 , in combination with the aminopeptidase inhibitor amastatin at 2.5 mmol kg 71 , facilitated gastrointestinal transit in a dose-dependent manner. The human PAR-1-derived peptide SFLLR-NH 2 and the speci®c PAR-1 agonist TFLLR-NH 2 , but not the inactive control FSLLR-NH 2 , at 2.5 ± 10 mmol kg 71 , in combination with amastatin, also promoted gastrointestinal transit. 3 The Ca 2+ -activated, small conductance K + channel inhibitor apamin at 0.01 mmol kg 71 signi®cantly potentiated the actions of SLIGRL-NH 2 and TFLLR-NH 2 at sube ective doses. 4 The increased gastrointestinal transit exerted by either SLIGRL-NH 2 at 5 mmol kg 71 or TFLLR-NH 2 at 10 mmol kg 71 was completely abolished by the L-type Ca 2+ channel inhibitor verapamil at 61.6 mmol kg 71 . In contrast, the tyrosine kinase inhibitor genistein at 18.5 mmol kg 71 failed to modify the e ects of the agonists for PAR-2 or PAR-1. 5 These ®ndings demonstrate that PAR-1 and PAR-2 modulate gastrointestinal transit in mice in vivo. Our data also suggest that the PAR-1-and PAR-2-mediated e ects are modulated by apaminsensitive K + channels and are dependent on activation of L-type Ca 2+ channels, but independent of tyrosine kinase. Our study thus provides novel evidence for the physiological and/or pathophysiological roles of PARs 1 and 2 in the digestive systems, most probably during in¯ammation.